文献速递头颈技术与安全PETCT

头颈部肿瘤治疗前及治疗中肿瘤乏氧、增殖与葡萄糖代谢的多示踪剂PET评估

Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment.
PubMed 文献 · Br J Radiol · 2020-01-02

本研究在33例局部晚期头颈部肿瘤患者放化疗前及治疗中行FDG、FLT和FMISO多示踪剂PET/CT成像,评估图像参数对预后的预测价值。治疗前各示踪剂最大标准化摄取值与预后无相关性;CT及FLT初始肿瘤体积与无病生存相关,FDG和FLT代谢肿瘤体积与局部控制相关。作者认为多示踪剂PET是可行且有前景的工具,但图像分析各环节尤其乏氧示踪剂仍需在统一方案和标准化的更大规模多中心研究中进一步临床验证。

要点

  • 治疗前FDG、FLT、FMISO的最大标准化摄取值与生存结局均无相关性。
  • 初始CT肿瘤体积和初始FLT体积与无病生存相关(p分别为0.007和0.04)。
  • FDG和FLT代谢肿瘤体积与局部控制显著相关(p分别为0.005和0.02)。

诊断标准与关键数值

  • 治疗前FDG、FLT、FMISO的最大标准化摄取值与总体生存、无病生存和局部控制均无相关性。
  • 初始CT扫描测得的肿瘤体积与无病生存相关(p=0.007),初始FLT体积与无病生存相关(p=0.04)。
  • FDG代谢肿瘤体积与局部控制显著相关(p=0.005),FLT代谢肿瘤体积与局部控制显著相关(p=0.02)。
  • 多因素Cox分析中仅初始个体TMRmax与总体生存相关。

临床应用与阅片要点

  • 监测肿瘤生物学特征的多示踪剂PET模式似乎是日常临床实践中可行的选择。
  • 乏氧亚体积的评估更依赖患者个体,因此需要探索乏氧的个体化参数。
  • 肿瘤与肌肉比值似乎是目前最有前景的指标。

局限性

  • 图像分析各方面尤其乏氧示踪剂需在采用统一成像方案和标准化的更大规模多中心研究中进一步临床验证。
  • 乏氧亚体积的评估更依赖患者个体,需要探索乏氧的个体化参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The aim of the study was to assess the feasibility of multitracer positron emission tomography (PET) imaging before and during chemoradiation and to evaluate the predictive value of image-based factors for outcome in locally advanced head and neck cancers treated with chemoradiation.

METHODS: In the week prior to the treatment [18F]-2-flu-2-deoxy-D-glucose (FDG), [18F]-3'-flu-3'deoxythymidine (FLT) and [18F]-flumisonidazole (FMISO) imaging was performed. FLT scans were repeated at 14 and 28 Gy and FMISO at 36 Gy. Overall survival, disease-free survival and local control were correlated with subvolume parameters, and with tumour-to-muscle ratio for FMISO. For every tracer, total metabolic tumour volume was calculated.

RESULTS: 33 patients were included. No correlation was found between pre-treatment maximum standardised uptake value for FDG, FLT, FMISO and outcomes. Tumour volume measured on initial CT scans and initial FLT volume correlated with disease-free survivall (p = 0.007 and 0.04 respectively). FDG and FLT metabolic tumour volumes correlated significantly with local control (p = 0.005 and 0.02 respectively). In multivariate Cox analysis only individual initial TMRmax correlated with overall survival.

CONCLUSION: PET/CT imaging is a promising tool. However, various aspects of image analysis need further clinical validation in larger multicentre study employing uniform imaging protocol and standardisation, especially for hypoxia tracer.

ADVANCES IN KNOWLEDGE: Monitoring of biological features of the tumour using multitracer PET modality seems to be a feasible option in daily clinical practice.Evaluation of hypoxic subvolumes is more patient dependent; thus, exploration of individual parameters of hypoxia is needed. tumour-to-muscle ratio seems to be the most promising so far.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Kazmierska J, Cholewinski W, Piotrowski T, et al. Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment. Br J Radiol. 2020. PMID: 31860336. doi:10.1259/bjr.20180781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。